- Home
- INKT vs PTHL Comparison
INKT vs PTHL Comparison
Compare INKT & PTHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- PTHL
- Stock Information
- Founded
- INKT 2017
- PTHL 1998
- Country
- INKT United States
- PTHL China
- Employees
- INKT N/A
- PTHL N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- PTHL
- Sector
- INKT Health Care
- PTHL
- Exchange
- INKT Nasdaq
- PTHL Nasdaq
- Market Cap
- INKT 36.7M
- PTHL 43.1M
- IPO Year
- INKT 2021
- PTHL 2024
- Fundamental
- Price
- INKT $10.10
- PTHL $3.00
- Analyst Decision
- INKT Strong Buy
- PTHL
- Analyst Count
- INKT 2
- PTHL 0
- Target Price
- INKT $6.50
- PTHL N/A
- AVG Volume (30 Days)
- INKT 70.0K
- PTHL 33.4K
- Earning Date
- INKT 03-20-2025
- PTHL 02-11-2025
- Dividend Yield
- INKT N/A
- PTHL N/A
- EPS Growth
- INKT N/A
- PTHL N/A
- EPS
- INKT N/A
- PTHL N/A
- Revenue
- INKT N/A
- PTHL $572,291.00
- Revenue This Year
- INKT N/A
- PTHL N/A
- Revenue Next Year
- INKT N/A
- PTHL N/A
- P/E Ratio
- INKT N/A
- PTHL N/A
- Revenue Growth
- INKT N/A
- PTHL 2.32
- 52 Week Low
- INKT $4.56
- PTHL $1.96
- 52 Week High
- INKT $19.00
- PTHL $6.45
- Technical
- Relative Strength Index (RSI)
- INKT 54.73
- PTHL N/A
- Support Level
- INKT $8.97
- PTHL N/A
- Resistance Level
- INKT $9.98
- PTHL N/A
- Average True Range (ATR)
- INKT 1.44
- PTHL 0.00
- MACD
- INKT -0.07
- PTHL 0.00
- Stochastic Oscillator
- INKT 42.97
- PTHL 0.00
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.